BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 10, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Targeted inhibition of both RAS and PIKfyve may offer a promising treatment approach for PDAC
To read the full story,
subscribe
or
sign in
.
Cancer
Targeted inhibition of both RAS and PIKfyve may offer a promising treatment approach for PDAC
May 2, 2025
No Comments
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal 5-year survival rate of 13%.
BioWorld Science
Cancer
